Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization |
| |
Authors: | Nagarajan Srinivasan R Lu Hwang-Fun Gasiecki Alan F Khanna Ish K Parikh Mihir D Desai Bipinchandra N Rogers Thomas E Clare Michael Chen Barbara B Russell Mark A Keene Jeffery L Duffin Tiffany Engleman V Wayne Finn Mary B Freeman Sandra K Klover Jon A Nickols G Alan Nickols Maureen A Shannon Kristen E Steininger Christina A Westlin William F Westlin Marisa M Williams Melanie L |
| |
Institution: | Pfizer Global Research and Development, St. Louis Laboratories, Pfizer, Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA. Srinivasan.Nagarajan@Pfizer.com |
| |
Abstract: | The integrin alpha(v)beta(3) is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal angiogenesis. The tripeptide Arg-Gly-Asp (RGD), a common binding motif in several ligands that bind to alpha(v)beta(3), has been depeptidized and optimized in our efforts toward discovering a small molecule inhibitor. We recently disclosed the synthesis and biological activity of several small molecules that did not contain any peptide bond and mimic the tripeptide RGD. The phenethyl group in one of the lead compounds was successfully replaced with a cyclopropyl moiety. The new lead compound was optimized for potency, selectivity, and for its ADME properties. We describe herein the discovery, synthesis, and optimization of cyclopropyl containing analogs that are potent and selective inhibitors of alpha(v)beta(3). |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|